Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 46 peer-reviewed journal articles Updated
Genetics

Understanding CPT II Deficiency: A Stabilizing Overview

At a Glance

Carnitine Palmitoyltransferase II (CPT II) deficiency is a rare genetic disorder that stops the body from using fat for energy during stress or fasting. With early diagnosis, dietary adjustments, and trigger management, most people with the common myopathic form can live active, fulfilling lives.

Receiving a diagnosis of Carnitine Palmitoyltransferase II (CPT II) deficiency can feel overwhelming, but understanding the basics is the first step toward managing it effectively. This is a rare genetic metabolic disorder that changes how the body creates energy [1][2]. While it requires lifelong attention, many people—especially those with the most common form—live active, fulfilling lives by making specific lifestyle adjustments [3][4].

How Your Body Uses Energy

To understand CPT II deficiency, it helps to think of your body’s energy system like a dual-fuel engine. Your body typically burns glucose (sugar) for quick energy and fatty acids (fats) for longer-term energy [1].

The CPT II enzyme acts like a gatekeeper. Its job is to help “long-chain fatty acids” enter the mitochondria, which are the power plants of your cells [1][5]. Once inside, these fats are burned for fuel. In CPT II deficiency, this gate is partially or fully blocked. This means that during times of “metabolic stress”—such as long periods without food (fasting), intense exercise, or illness—the body cannot access its fat stores for the energy it needs [6][2].

The Three Clinical Forms

CPT II deficiency is not the same for everyone. It is categorized into three main types based on when symptoms start and how they affect the body:

  1. Myopathic Form (Most Common): This form usually appears in older children, teenagers, or adults [7][8]. It primarily affects the muscles. People with this form may experience muscle pain (myalgia) or weakness, especially after exercise or during a fever [9][3].
  2. Severe Infantile Form: This form begins in infancy and involves multiple organs, including the liver, heart, and kidneys [10][11].
  3. Lethal Neonatal Form: This is the rarest and most severe form, appearing in the first days of life with significant symptoms affecting the heart and brain [10][12].

Stabilizing Facts for Families

While a new diagnosis is a major life event, several key facts can provide a sense of control:

  • Triggers are manageable: Most metabolic crises are caused by known triggers like prolonged fasting, intense physical exertion, cold exposure, or viral infections [3][8]. Learning to manage these can prevent episodes.
  • The prognosis is often positive: For those with the myopathic form, the long-term outlook is generally very good when the condition is diagnosed early and managed correctly [4][7].
  • Dietary changes are a powerful tool: Simple dietary changes, such as a high-carbohydrate diet and avoiding long gaps between meals, can provide the body with the steady glucose fuel it needs [7][6].
  • Medical advances exist: New therapies, such as triheptanoin (an oil that provides a different type of fuel), are now available to help the body bypass the enzyme block [13][14].

Diagnosis and Monitoring

Doctors often use acylcarnitine profiling or genetic testing to confirm the diagnosis [15][6]. Because some screening tests can look normal in between episodes, genetic testing is often the most definitive way to confirm the condition [16][17].

One important marker doctors watch is creatine kinase (CK). When muscles are stressed or damaged, they leak CK into the blood [3]. Monitoring your physical symptoms, along with checking for myoglobinuria (dark-colored urine), helps you and your care team know if the body is struggling and needs intervention, such as extra hydration [8][18].

In this guide

4 chapters

01

The Three Subtypes and Symptoms of CPT II Deficiency

Learn about the three subtypes of CPT II deficiency. Understand key symptoms, common triggers like fasting, and warning signs like dark urine or muscle pain.

02

Diagnosis, Genetics, and Lab Results for CPT II Deficiency

Learn how CPT II deficiency is diagnosed. Understand newborn screening limits, lab markers like CK and acylcarnitines, and CPT2 genetic test results.

03

Standard of Care: Treatment and Management of CPT II Deficiency

Learn how to manage CPT II deficiency. Understand essential dietary changes, avoiding triggers like fasting and exercise, and handling a metabolic crisis.

04

Building Your Care Team and Day-to-Day Living

Learn how to build a care team for CPT II deficiency. Understand the role of metabolic specialists, how to create an emergency letter, and manage daily life.

Common questions in this guide

What are the different types of CPT II deficiency?
There are three main types based on when symptoms begin. The most common is the myopathic form, which affects older children and adults by causing muscle pain. The more severe forms are the severe infantile and lethal neonatal types, which appear in babies and affect multiple organs.
What triggers a CPT II deficiency metabolic crisis?
Episodes are usually triggered by times of metabolic stress when the body needs to burn fat for energy. Common triggers include prolonged fasting, intense physical exercise, cold exposure, and viral illnesses or fevers.
How is CPT II deficiency managed and treated?
Treatment focuses on preventing metabolic crises through dietary changes, like eating a high-carbohydrate diet and avoiding long periods without food. Medical therapies like triheptanoin or MCT oil may also be prescribed to provide the body with an alternative energy source.
Why do I need to monitor my urine color with CPT II deficiency?
Dark-colored urine is a sign of muscle breakdown, a condition called myoglobinuria. It indicates that your body is in distress and needs immediate medical intervention, such as intravenous hydration, to prevent kidney damage.
How is CPT II deficiency diagnosed?
Doctors typically diagnose the condition using a combination of blood tests, such as acylcarnitine profiling, and genetic testing. Since routine tests can appear normal between episodes, genetic testing is often the most reliable way to confirm the diagnosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which clinical form of CPT II deficiency (myopathic, severe infantile, or lethal neonatal) is my child/am I currently diagnosed with?
  2. 2.What is the current fasting tolerance—the maximum amount of time we can safely go without food—for this age and condition?
  3. 3.Can you provide a written 'Emergency Letter' for us to give to ER doctors during a fever or illness?
  4. 4.Are there specific carbohydrate-loading protocols we should use before physical activities?
  5. 5.Is a prescription for triheptanoin (Dojolvi) or MCT oil appropriate for our specific situation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach.

    Joshi PR, Zierz S

    Molecules (Basel, Switzerland) 2020; (25(8)) doi:10.3390/molecules25081784.

    PMID: 32295037
  2. 2

    Carnitine Palmitoyltransferase II (CPT2) Deficiency: An Overlooked and Elusive Cause of Acute Kidney Injury.

    Seferi S, Saliaj K, Likaj E, Rroji M

    Cureus 2024; (16(9)):e70442 doi:10.7759/cureus.70442.

    PMID: 39473663
  3. 3

    Myopathic Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Rare Cause of Acute Kidney Injury and Cardiomyopathy.

    Castillo E, Medina D, Schoenmann N

    Cureus 2023; (15(10)):e46595 doi:10.7759/cureus.46595.

    PMID: 37933340
  4. 4

    Clinical characteristics and genetic analysis of six children with carnitine palmitoyltransferase 2 deficiency.

    Zhang Y, Qiu W, Zhang H, et al.

    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2024; (53(2)):207-212 doi:10.3724/zdxbyxb-2023-0611.

    PMID: 38650450
  5. 5

    Mitochondrial carnitine palmitoyltransferase-II dysfunction: A possible novel mechanism for nonalcoholic fatty liver disease in hepatocarcinogenesis.

    Yao M, Zhou P, Qin YY, et al.

    World journal of gastroenterology 2023; (29(12)):1765-1778 doi:10.3748/wjg.v29.i12.1765.

    PMID: 37032731
  6. 6

    Carnitine palmitoyltransferase-II deficiency: case presentation and review of the literature.

    Mccormick BJ, Chirila RM

    Romanian journal of internal medicine = Revue roumaine de medecine interne 2021; (59(4)):420-424 doi:10.2478/rjim-2021-0021.

    PMID: 34118800
  7. 7

    Recurrent rhabdomyolysis caused by carnitine palmitoyltransferase II deficiency, common but under-recognised: Lessons to be learnt.

    Balasubramanian M, Jenkins TM, Kirk RJ, et al.

    Molecular genetics and metabolism reports 2018; (15()):69-70 doi:10.1016/j.ymgmr.2018.02.008.

    PMID: 29744303
  8. 8

    Recurrent Myalgia since Early Infancy-Misleading Clinical Course in a Child with Carnitine Palmitoyltransferase-II Deficiency.

    Arélin M, Zierz S, Ceglarek U, et al.

    Neuropediatrics 2020; (51(1)):53-56 doi:10.1055/s-0039-1694977.

    PMID: 31541997
  9. 9

    Carnitine palmitoyltransferase II deficiency with a focus on newborn screening.

    Tajima G, Hara K, Yuasa M

    Journal of human genetics 2019; (64(2)):87-98 doi:10.1038/s10038-018-0530-z.

    PMID: 30514913
  10. 10

    Carnitine palmitoyltransferase II (CPT II) deficiency responsible for refractory cardiac arrhythmias, acute multiorgan failure and early fatal outcome.

    Serra G, Antona V, Insinga V, et al.

    Italian journal of pediatrics 2024; (50(1)):67 doi:10.1186/s13052-024-01632-x.

    PMID: 38616285
  11. 11

    Successful orthotopic heart transplantation in CPTII deficiency.

    Arnold GL, Yester J, McCracken E, et al.

    Molecular genetics and metabolism 2021; (133(2)):182-184 doi:10.1016/j.ymgme.2021.04.005.

    PMID: 34020866
  12. 12

    Neonatal Carnitine Palmitoyltransferase II Deficiency: A Lethal Entity.

    Malik S, Paldiwal AA, Korday CS, Jadhav SS

    Journal of clinical and diagnostic research : JCDR 2015; (9(10)):SD01-2 doi:10.7860/JCDR/2015/13600.6560.

    PMID: 26557586
  13. 13

    Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases.

    Wehbe Z, Tucci S

    Journal of inherited metabolic disease 2020; (43(3)):385-391 doi:10.1002/jimd.12199.

    PMID: 31778232
  14. 14

    Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid β-oxidation deficient cells: A comparative study.

    Karunanidhi A, Van't Land C, Rajasundaram D, et al.

    Journal of inherited metabolic disease 2022; (45(3)):541-556 doi:10.1002/jimd.12480.

    PMID: 35076099
  15. 15

    Severe rhabdomyolysis in an infant due to fatty acid oxidation disorder: a case report.

    Krug A, Perlot P, Empain A, et al.

    Journal of medical case reports 2025; (19(1)):291 doi:10.1186/s13256-025-05350-8.

    PMID: 40545541
  16. 16

    Recurrent rhabdomyolysis caused by palmitoyltransferase II (CPT-2) deficiency but complete normal acylcarnitine profile: A patient presentation and review of the literature.

    Lu CH, Yang CF, Chen YR, et al.

    Molecular genetics and metabolism reports 2024; (41()):101151 doi:10.1016/j.ymgmr.2024.101151.

    PMID: 39429887
  17. 17

    Missed Newborn Screening Case of Carnitine Palmitoyltransferase-II Deficiency.

    Edmondson AC, Salant J, Ierardi-Curto LA, Ficicioglu C

    JIMD reports 2017; (33()):93-97 doi:10.1007/8904_2016_528.

    PMID: 27067077
  18. 18

    Carnitine palmitoyltransferase II deficiency and post-COVID vaccination rhabdomyolysis.

    Tan A, Stepien KM, Narayana STK

    QJM : monthly journal of the Association of Physicians 2021; (114(8)):596-597 doi:10.1093/qjmed/hcab077.

    PMID: 33871650

This page provides an educational overview of CPT II deficiency and its management. Always consult your geneticist or metabolic specialist for personalized dietary plans, fasting guidelines, and treatment protocols.

Get notified when new evidence is published on Carnitine palmitoyltransferase II deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.